Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent HCP Stock Price: $25.78
Summary: HashiCorp Inc. is a cloud adoption software company. HashiCorp Inc. is based in California.
Ittai Kidron analyst at Oppenheimer reiterates coverage on HashiCorp (HCP) stock in the energy sector with a Buy rating and has set HCP's stock price target at $ 42.
TipRanks.com reports that HashiCorp currently has 15 analysts offering 12-month price targets on HCP and the consensus is a Moderate Buy rating with an average stock price target of $42.89. The most recent HCP stock price we have is $25.78 and we are not making any HCP forecasts at this time.
In addition, TradingView issued a Strong Sell rating for HCP over the next month, Barchart.com has a hold rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on HCP. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on HCP, please click here >>
Biogen, BIIB
Recent BIIB Stock Price: $308.88
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Ami Fadia analyst at Needham reiterates coverage on Biogen (BIIB) stock in the energy sector with a Buy rating and has set BIIB's stock price target at $ 321.
TipRanks.com reports that Biogen currently has 13 analysts offering 12-month price targets on BIIB and the consensus is a Strong Buy rating with an average stock price target of $293.88. The most recent BIIB stock price we have is $308.88 and we are not making any BIIB forecasts at this time.
In addition, TradingView issued a Buy rating for BIIB over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BIIB. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BIIB, please click here >>
Doximity, DOCS
Recent DOCS Stock Price: $31.93
Summary: Doximity Inc. provides digital platform for medical professionals. The company's network members include physicians across all specialties and practice areas. It provide its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and conduct virtual patient visits. Doximity Inc. is based in SAN FRANCISCO.
Jessica Tassan analyst at Piper Sandler reiterates coverage on Doximity (DOCS) stock in the energy sector with a Buy rating and has set DOCS's stock price target at $ 38.
TipRanks.com reports that Doximity currently has 18 analysts offering 12-month price targets on DOCS and the consensus is a Moderate Buy rating with an average stock price target of $33.50. The most recent DOCS stock price we have is $31.93 and we are not making any DOCS forecasts at this time.
In addition, TradingView issued a Strong Sell rating for DOCS over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on DOCS. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DOCS, please click here >>
Replimune Group, REPL
Recent REPL Stock Price: $22.56
Summary: Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States.
Robert Burns analyst at H.C. Wainwright reiterates coverage on Replimune Group (REPL) stock in the energy sector with a Buy rating and has set REPL's stock price target at $ 51.
TipRanks.com reports that Replimune Group currently has 15 analysts offering 12-month price targets on REPL and the consensus is a Strong Buy rating with an average stock price target of $49.00. The most recent REPL stock price we have is $22.56 and we are not making any REPL forecasts at this time.
In addition, TradingView issued a Buy rating for REPL over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on REPL. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on REPL, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
==============================================================================
